| Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. N Bhala, J Emberson, A Merhi, S Abramson, N Arber, JA Baron, ... Lancet (London, England) 382 (9894), 769-779, 2013 | 1611 | 2013 |
| Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 P McGettigan, D Henry Jama 296 (13), 1633-1644, 2006 | 1528 | 2006 |
| Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies P McGettigan, D Henry PLoS medicine 8 (9), e1001098, 2011 | 768 | 2011 |
| Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries P McGettigan, D Henry PLoS medicine 10 (2), e1001388, 2013 | 538 | 2013 |
| Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message P McGettigan, J Golden, J Fryer, R Chan, J Feely British journal of clinical pharmacology 51 (2), 184-189, 2001 | 262 | 2001 |
| Cardiovascular effects and safety of (non-aspirin) NSAIDs AM Schjerning, P McGettigan, G Gislason Nature Reviews Cardiology 17 (9), 574-584, 2020 | 226 | 2020 |
| Describing treatment effects to patients: How they are expressed makes a difference A Moxey, D O’Connell, P McGettigan, D Henry Journal of General Internal Medicine 18 (11), 948-959, 2003 | 221 | 2003 |
| Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction AMS Olsen, GH Gislason, P McGettigan, E Fosbøl, R Sørensen, ... Jama 313 (8), 805-814, 2015 | 195 | 2015 |
| The effects of information framing on the practices of physicians P McGettigan, K Sly, D O'connell, S Hill, D Henry Journal of general internal medicine 14 (10), 633-642, 1999 | 174 | 1999 |
| Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. D Henry, P McGettigan International journal of clinical practice. Supplement, 43-49, 2003 | 138 | 2003 |
| Reporting of adverse drug reactions by hospital doctors and the response to intervention P McGettigan, J Golden, RM Conroy, N Arthur, J Feely British journal of clinical pharmacology 44 (1), 98-100, 1997 | 129 | 1997 |
| Response rates and representativeness: a lottery incentive improves physician survey return rates J Robertson, EJ Walkom, P McGettigan Pharmacoepidemiology and drug safety 14 (8), 571-577, 2005 | 92 | 2005 |
| Current problems with non-specific COX inhibitors P McGettigan, D Henry Current pharmaceutical design 6 (17), 1693-1724, 2000 | 89 | 2000 |
| Lipid peroxidation and antioxidant vitamins C and E in hypertensive patients Y Wen, S Killalea, P McGettigan, J Feely Irish journal of medical science 165, 210-212, 1996 | 81 | 1996 |
| The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis J Attia, A Thakkinstian, Y Wang, L Lincz, M Parsons, J Sturm, ... Journal of stroke and cerebrovascular diseases 16 (4), 173-179, 2007 | 80 | 2007 |
| Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments P McGettigan, C Alonso Olmo, K Plueschke, M Castillon, ... Drug safety 42, 1343-1351, 2019 | 78 | 2019 |
| Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy D Morales, A Pacurariu, J Slattery, L Pinheiro, P McGettigan, X Kurz JAMA neurology 76 (7), 827-833, 2019 | 77 | 2019 |
| Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case–control study DR Morales, J Slattery, A Pacurariu, L Pinheiro, P McGettigan, X Kurz Clinical drug investigation 39, 205-213, 2019 | 75 | 2019 |
| Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or … P McGettigan, P Roderick, R Mahajan, A Kadam, AM Pollock PLoS medicine 12 (5), e1001826, 2015 | 71 | 2015 |
| Growth in use of statins after trials is not targeted to most appropriate patients J Feely, P McGettigan, A Kelly Clinical Pharmacology & Therapeutics 67 (4), 438-441, 2000 | 66 | 2000 |
